Literature DB >> 3985057

Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma.

W T Creasman, J T Soper, K S McCarty, K S McCarty, W Hinshaw, D L Clarke-Pearson.   

Abstract

The clinicopathologic associations and effect on prognosis of cytoplasmic steroid receptor content were studied in 168 patients with clinical Stage I and II endometrial carcinoma. Cytoplasmic estrogen receptor status was associated (p less than 0.01) with histologic differentiation, nuclear differentiation, and histologic documentation of extrauterine metastases. Progesterone receptor status was related (p less than 0.05) to histologic differentiation and histologic cell type, and combined estrogen receptor/progesterone receptor status was associated (p less than 0.05) with histologic differentiation, peritoneal cytology, extrauterine metastases, and histologic cell type among the 105 patients who had determination of both estrogen and progesterone receptors. Single-factor analysis revealed significant (p less than 0.05) effects of estrogen receptor status, progesterone receptor status, and estrogen receptor/progesterone receptor status on disease-free survival. All other clinicopathologic features significantly (p less than 0.05) affected prognosis, except for peritoneal cytology. With use of stepwise regression analysis of proportional hazards, estrogen receptor, progesterone receptor, and combined estrogen receptor/progesterone receptor status were significant independent prognostic factors, replacing histologic assessment of glandular or nuclear differentiation in the models. These data suggest that receptor status of primary endometrial carcinomas provides important information relevant to tumor behavior which complements the information provided by conventional clinicopathologic analysis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3985057     DOI: 10.1016/0002-9378(85)90671-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

1.  [Progesterone receptors in endometrial cancer--a deciding prognostic factor].

Authors:  W Kleine; W Bergmann; H Geyer; H Pfleiderer
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 2.  What have we learned about GPER function in physiology and disease from knockout mice?

Authors:  Eric R Prossnitz; Helen J Hathaway
Journal:  J Steroid Biochem Mol Biol       Date:  2015-07-16       Impact factor: 4.292

3.  Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.

Authors:  Basil R Obeidat; Ismail I Matalka; Alia A Mohtaseb; Nabih S Al-Kaisi
Journal:  Pathol Oncol Res       Date:  2012-10-10       Impact factor: 3.201

Review 4.  Pathophysiology and management of endometrial hyperplasia and carcinoma.

Authors:  Y S Fu; J C Gambone; J S Berek
Journal:  West J Med       Date:  1990-07

5.  DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinoma.

Authors:  R Punnonen; J Mattila; T Kuoppala; T Koivula
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 6.  The predictive value of steroid hormone receptor analysis in breast, endometrial and ovarian cancer.

Authors:  R Vihko; A Alanko; V Isomaa; A Kauppila
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

Review 7.  Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.

Authors:  Tanri Shiozawa; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2006-02       Impact factor: 3.850

Review 8.  Sex steroid receptors in endometrial cancer.

Authors:  J T Chambers
Journal:  Yale J Biol Med       Date:  1988 Jul-Aug

Review 9.  Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.

Authors:  Yanli Zhang; Dong Zhao; Changguo Gong; Fengmei Zhang; Jing He; Wei Zhang; Yulan Zhao; Jing Sun
Journal:  World J Surg Oncol       Date:  2015-06-25       Impact factor: 2.754

10.  Nucleophosmin/B23 is a negative regulator of estrogen receptor α expression via AP2γ in endometrial cancer cells.

Authors:  Chiao-Yun Lin; Angel Chao; Tzu-Hao Wang; Li-Yu Lee; Lan-Yan Yang; Chia-Lung Tsai; Hsin-Shih Wang; Chyong-Huey Lai
Journal:  Oncotarget       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.